Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX1903 in Relapsed/Refractory Hematologic Malignancies and AML
CTR20212017Phase 2Terminated
- Sponsor
- CSPC Pharmaceutical Group
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of syhx1903 in hematopoietic malignancies, acute myeloid leukemia (AML), lymphoma, multiple myeloma (MM), sponsored by CSPC Pharmaceutical Group. Started Sep 2021; status: terminated.
02
Drugs
syhx1903
03
Conditions
hematopoietic malignanciesacute myeloid leukemia (AML)lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on CTR20212017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212017.